Stereotactic Radiotherapy Reduces Treatment Cost while Improving Overall Survival and Local Control over Standard Fractionated Radiation Therapy for Medically Inoperable Non–small Cell Lung Cancer

Lanni, Thomas B.; Grills, I.S.; Kestin, Larry L.; Marvin, K.; Robertson, John M.; Shah, Chirag; Ye, H.; Martínez, Álvaro

doi:10.1016/j.ijrobp.2009.07.1015

Cited by 19 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Liao et al [7] showed that not only does 4DCT-IMRT yield less toxicity than 3D-CRT, but also better survival in non-small cell lung cancer (NSCLC). Similarly, Lanni et al [8] found SBRT to be less expensive than standard fractionated EBRT and also associated with superior local control and overall survival in stage I NSCLC patients. As more results are published, it is expected that these sophisticated new technologies will prove to yield superior survival outcomes.…”

Section: Promisesmentioning

confidence: 94%

Promises and pitfalls of new technology in radiotherapy

Guedea

2012

Clin Transl Oncol

View full text Add to dashboard Cite

Section: Promisesmentioning

confidence: 94%

Promises and pitfalls of new technology in radiotherapy

Guedea

2012

Clin Transl Oncol

View full text Add to dashboard Cite

“…The disease site most often evaluated in rt costing studies was prostate cancer (39%) 7,9,10,[15][16][17][18]24,27,29,31,32,34 , followed by breast cancer (18%) 8,19,22,25,26,28 , non-smallcell lung cancer (12%) 20,23,37,39 , head-and-neck cancer (9%) 14,33,38 , cervical cancer (6%) 13,21 , and other sites [bone metastases (6%) 12,30 , metastatic epidural spinal cord (3%) 36 , oropharyngeal cancer (3%) 35 , and squamous cell cancer of the anus (3%) 11 ]. Thirteen studies used original costing data to conduct the costing analysis 8,19,20,[24][25][26]28,[29][30][31][32][33]37 ; the remaining twenty studies modelled outcomes using hypothetical patient cohorts 7,…”

Section: Methods In the Included Studiesmentioning

confidence: 99%

“…As shown in Figure 2, twenty-two studies provided costs for imrt 7,[9][10][11]14,[16][17][18][19][20][21][22][23][24]27,28,29,[31][32][33][34][35] ; sixteen, for 3D-c rt 11,14,15,17,19,20,22,23,28,[31][32][33][34][35]37,39 ; six, for bt 9,13,22,24,31,32 ; and six, for sbrt 7,10,20,23,27,37 . A number of studies also costed other modalities of rt (rt in general, whole-breast radiation, external-beam partial-breast irradiation, etc.…”

Section: Methods In the Included Studiesmentioning

confidence: 99%

“…The cost for imrt ranged from US$2,687.87 to US$111,900.60 per treatment, followed by 3D-crt at US$5,583.28 to US$90,055, bt at US$10,544.22 to US$78,667.40, and sbrt at US$6,520.58 to US$19,602.68. Studies by Lanni et al 20 and Shah et al 24 included institutional costs in addition to the hospital-specific reimbursement for rt treatment.…”

Section: Methods In the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Radiation Costing Methods: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

Objective Costs for radiation therapy (rt) and the methods used to cost rt are highly diverse across the literature.To date, no study has compared various costing methods in detail. Our objective was to perform a thorough review of the radiation costing literature to identify sources of costs and methods used.Methods A systematic review of Ovid medline, Ovid oldmedline, embase, Ovid HealthStar, and EconLit from 2005 to 23 March 2015 used search terms such as "radiation," "radiotherapy," "neoplasm," "cost," " cost analysis," and "cost benefit analysis" to locate relevant articles. Original papers were reviewed for detailed costing methods. Cost sources and methods were extracted for papers investigating rt modalities, including three-dimensional conformal rt (3D-crt), intensity-modulated rt (imrt), stereotactic body rt (sbrt), and brachytherapy (bt). All costs were translated into 2014 U.S. dollars. ResultsMost of the studies (91%) reported in the 33 articles retrieved provided rt costs from the health system perspective. The cost of rt ranged from US$2,687.87 to US$111,900.60 per treatment for imrt, followed by US$5,583.28 to US$90,055 for 3D-crt, US$10,544.22 to US$78,667.40 for bt, and US$6,520.58 to US$19,602.68 for sbrt. Cost drivers were professional or personnel costs and the cost of rt treatment. Most studies did not address the cost of rt equipment (85%) and institutional or facility costs (66%). ConclusionsCosting methods and sources were widely variable across studies, highlighting the need for consistency in the reporting of rt costs. More work to promote comparability and consistency across studies is needed.

show abstract

“…A study from William Beaumont Hospital by Lanni et al 33 analysis demonstrated significant 3-year overall survival benefit using SBRT, 71% versus 42% for EBRT (P < 0.05). SBRT also reduced local failure compared with EBRT (12% vs. 34%, P = 0.10).…”

Section: Stereotactic Body Radiotherapy Versus Ebrtmentioning

confidence: 99%

Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer Patients

Abboud¹,

Teh²,

Blackmon³

et al. 2012

Clinical Pulmonary Medicine

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths in the United States. Only a small percentage of patients with non-small cell lung cancer present with early-stage disease. The standard curative treatment is lobectomy but patients with lung cancer frequently have comorbidities, rendering them unsuitable for surgical resection. Conventional radiotherapy has been used as a nonsurgical alternative for patients with early-stage non-small cell lung cancer but the outcomes are inferior to surgical resection. Stereotactic body radiation therapy (SBRT) has emerged as a promising treatment for medically inoperable early-stage non-small cell lung cancer with local control rates exceeding 90%, rivaling surgical resection. Multiple retrospective studies and prospective trials across the world have consistently demonstrated high local control rates and low rates of severe toxicities. Currently, multiple phase II and randomized phase III trials are ongoing, attempting to determine optimal SBRT regimen for different clinical scenarios and to compare SBRT with surgery.

show abstract

Stereotactic Radiotherapy Reduces Treatment Cost while Improving Overall Survival and Local Control over Standard Fractionated Radiation Therapy for Medically Inoperable Non–small Cell Lung Cancer

Cited by 19 publications

References 0 publications

Promises and pitfalls of new technology in radiotherapy

Promises and pitfalls of new technology in radiotherapy

Radiation Costing Methods: A Systematic Review

Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer Patients

Contact Info

Product

Resources

About